Compile Data Set for Download or QSAR
maximum 50k data
Found 20 Enz. Inhib. hit(s) with all data for entry = 6606
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141376(US8916600, 10 | US9738632, Example 10)
Affinity DataIC50:  0.647nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141385(US8916600, 19 | US9738632, Example 19)
Affinity DataIC50:  0.663nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141378(US8916600, 12 | US9738632, Example 12)
Affinity DataIC50:  0.767nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141374(US8916600, 8)
Affinity DataIC50:  0.796nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141379(US8916600, 13 | US9738632, Example 13)
Affinity DataIC50:  0.817nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141372(US8916600, 6 | US9738632, Example 6)
Affinity DataIC50:  0.913nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141383(US8916600, 17 | US9738632, Example 17)
Affinity DataIC50:  0.996nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141371(US8916600, 5 | US9738632, Example 5)
Affinity DataIC50:  1.08nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141375(US8916600, 9 | US9738632, Example 9)
Affinity DataIC50:  1.09nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141373(US8916600, 7 | US9738632, Example 8)
Affinity DataIC50:  1.30nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141367(US8916600, 1 | US8916600, 4 | US9738632, Example 1)
Affinity DataIC50:  1.32nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141368(US8916600, 2 | US8916600, 3 | US9738632, Example 2)
Affinity DataIC50:  1.36nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141367(US8916600, 1 | US8916600, 4 | US9738632, Example 1)
Affinity DataIC50:  1.40nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141368(US8916600, 2 | US8916600, 3 | US9738632, Example 2)
Affinity DataIC50:  1.60nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141380(US8916600, 14 | US9738632, Example 14)
Affinity DataIC50:  1.75nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141386(US8916600, 20 | US9738632, Example 20)
Affinity DataIC50:  1.96nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141377(US8916600, 11 | US9738632, Example 11)
Affinity DataIC50:  2.15nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141384(US8916600, 18 | US9738632, Example 18)
Affinity DataIC50:  3.44nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141381(US8916600, 15 | US8916600, 16 | US9738632, Example...)
Affinity DataIC50:  3.64nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGlucocorticoid receptor(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM141381(US8916600, 15 | US8916600, 16 | US9738632, Example...)
Affinity DataIC50:  4.27nMpH: 7.4 T: 2°CAssay Description:In the GR radioligand binding assay, test compounds were serially diluted in semi-log steps (10 concentrations) with a final concentration of 10 uM. ...More data for this Ligand-Target Pair
In DepthDetails US Patent